Cargando…

Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

The purpose of androgen deprivation therapy (ADT) in prostate cancer (PCa), using luteinizing hormone-releasing hormone agonists (LHRHa) or gonadotrophin-releasing hormone antagonists, is to suppress the levels of testosterone. Since testosterone is the precursor of estradiol (E2), one of the major...

Descripción completa

Detalles Bibliográficos
Autores principales: Coelingh Bennink, Herjan J T, Krijgh, Jan, Egberts, Jan F M, Slootweg, Maria, van Melick, Harm H E, Roos, Erik P M, Somford, Diederik M, Zimmerman, Yvette, Schultz, Iman J, Clarke, Noel W, van Moorselaar, R Jeroen A, Debruyne, Frans M J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716371/
https://www.ncbi.nlm.nih.gov/pubmed/36283120
http://dx.doi.org/10.1530/EC-22-0182
_version_ 1784842674569740288
author Coelingh Bennink, Herjan J T
Krijgh, Jan
Egberts, Jan F M
Slootweg, Maria
van Melick, Harm H E
Roos, Erik P M
Somford, Diederik M
Zimmerman, Yvette
Schultz, Iman J
Clarke, Noel W
van Moorselaar, R Jeroen A
Debruyne, Frans M J
author_facet Coelingh Bennink, Herjan J T
Krijgh, Jan
Egberts, Jan F M
Slootweg, Maria
van Melick, Harm H E
Roos, Erik P M
Somford, Diederik M
Zimmerman, Yvette
Schultz, Iman J
Clarke, Noel W
van Moorselaar, R Jeroen A
Debruyne, Frans M J
author_sort Coelingh Bennink, Herjan J T
collection PubMed
description The purpose of androgen deprivation therapy (ADT) in prostate cancer (PCa), using luteinizing hormone-releasing hormone agonists (LHRHa) or gonadotrophin-releasing hormone antagonists, is to suppress the levels of testosterone. Since testosterone is the precursor of estradiol (E2), one of the major undesired effects of ADT is the concomitant loss of E2, causing among others an increased bone turnover and bone loss and an increased risk of osteoporosis and fractures. Therefore, the guidelines for ADT indicate to combine ADT routinely with bone-sparing agents such as bisphosphonates, denosumab or selective estrogen receptor modulators. However, these compounds may have side effects and some require inconvenient parenteral administration. Co-treatment with estrogens is an alternative approach to prevent bone loss and at the same time, to avoid other side effects caused by the loss of estrogens, which is the topic explored in the present narrative review. Estrogens investigated in PCa patients include parenteral or transdermal E2, diethylstilbestrol (DES), and ethinylestradiol (EE) as monotherapy, or high-dose estetrol (HDE4) combined with ADT. Cardiovascular adverse events have been reported with parenteral E2, DES and EE. Encouraging effects on bone parameters have been obtained with transdermal E2 (tE2) and HDE4, in the tE2 development program (PATCH study), and in the LHRHa/HDE4 co-treatment study (PCombi), respectively. Confirmation of the beneficial effects of estrogen therapy with tE2 or HDE4 on bone health in patients with advanced PCa is needed, with special emphasis on bone mass and fracture rate.
format Online
Article
Text
id pubmed-9716371
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-97163712022-12-06 Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review Coelingh Bennink, Herjan J T Krijgh, Jan Egberts, Jan F M Slootweg, Maria van Melick, Harm H E Roos, Erik P M Somford, Diederik M Zimmerman, Yvette Schultz, Iman J Clarke, Noel W van Moorselaar, R Jeroen A Debruyne, Frans M J Endocr Connect Review The purpose of androgen deprivation therapy (ADT) in prostate cancer (PCa), using luteinizing hormone-releasing hormone agonists (LHRHa) or gonadotrophin-releasing hormone antagonists, is to suppress the levels of testosterone. Since testosterone is the precursor of estradiol (E2), one of the major undesired effects of ADT is the concomitant loss of E2, causing among others an increased bone turnover and bone loss and an increased risk of osteoporosis and fractures. Therefore, the guidelines for ADT indicate to combine ADT routinely with bone-sparing agents such as bisphosphonates, denosumab or selective estrogen receptor modulators. However, these compounds may have side effects and some require inconvenient parenteral administration. Co-treatment with estrogens is an alternative approach to prevent bone loss and at the same time, to avoid other side effects caused by the loss of estrogens, which is the topic explored in the present narrative review. Estrogens investigated in PCa patients include parenteral or transdermal E2, diethylstilbestrol (DES), and ethinylestradiol (EE) as monotherapy, or high-dose estetrol (HDE4) combined with ADT. Cardiovascular adverse events have been reported with parenteral E2, DES and EE. Encouraging effects on bone parameters have been obtained with transdermal E2 (tE2) and HDE4, in the tE2 development program (PATCH study), and in the LHRHa/HDE4 co-treatment study (PCombi), respectively. Confirmation of the beneficial effects of estrogen therapy with tE2 or HDE4 on bone health in patients with advanced PCa is needed, with special emphasis on bone mass and fracture rate. Bioscientifica Ltd 2022-10-25 /pmc/articles/PMC9716371/ /pubmed/36283120 http://dx.doi.org/10.1530/EC-22-0182 Text en © The authors https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Review
Coelingh Bennink, Herjan J T
Krijgh, Jan
Egberts, Jan F M
Slootweg, Maria
van Melick, Harm H E
Roos, Erik P M
Somford, Diederik M
Zimmerman, Yvette
Schultz, Iman J
Clarke, Noel W
van Moorselaar, R Jeroen A
Debruyne, Frans M J
Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
title Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
title_full Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
title_fullStr Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
title_full_unstemmed Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
title_short Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
title_sort maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716371/
https://www.ncbi.nlm.nih.gov/pubmed/36283120
http://dx.doi.org/10.1530/EC-22-0182
work_keys_str_mv AT coelinghbenninkherjanjt maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview
AT krijghjan maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview
AT egbertsjanfm maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview
AT slootwegmaria maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview
AT vanmelickharmhe maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview
AT rooserikpm maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview
AT somforddiederikm maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview
AT zimmermanyvette maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview
AT schultzimanj maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview
AT clarkenoelw maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview
AT vanmoorselaarrjeroena maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview
AT debruynefransmj maintainingbonehealthbyestrogentherapyinpatientswithadvancedprostatecanceranarrativereview